Orgenesis Schedules First Quarter 2021 Business Update Conference Call
Orgenesis (NASDAQ: ORGS) announced a conference call to discuss corporate progress on May 7, 2021, at 8:30 AM ET. Analysts and investors can join the call via telephone or webcast. The call will be accessible again as a replay on the Investor Events section of their website. Orgenesis aims to enhance cell and gene therapies through its POCare Platform, which promotes affordable and accessible treatments. This platform includes licensed therapeutics and focuses on decentralized production at the point of care, collaborating with various stakeholders worldwide.
- Announcement of a conference call for May 7, 2021, to discuss corporate progress.
- Utilization of the POCare Platform to enhance accessibility to cell and gene therapies.
- None.
GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Friday, May 7, 2021 to discuss the Company’s corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or for international callers +1 973-528-0011 and using entry code 173027. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2585/41278 or on the Company’s Investor Events section of the website here.
A webcast replay will be available on the Company’s Investor Events section of the website (https://ir.orgenesis.com/events#/) through Saturday, May 07, 2022. A telephone replay of the call will be available approximately one hour following the call, through Friday, May 21, 2021 and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 41278.
About Orgenesis
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing at www.orgenesis.com.
Contact for Orgenesis:
David Waldman
Crescendo Communications, LLC
Tel: 212-671-1021
FAQ
What is the date of the Orgenesis conference call?
How can I access the Orgenesis conference call?
What is the POCare Platform by Orgenesis?
Where can I find the webcast for the Orgenesis conference call?
What is the focus of Orgenesis as a biotech company?
